Literature DB >> 12760860

Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.

George G Zhanel1, Lorraine Palatnick, Kimberly A Nichol, Tracy Bellyou, Don E Low, Daryl J Hoban.   

Abstract

A total of 6,991 unique patient isolates of Streptococcus pneumoniae were collected from October 1997 to June 2002 from 25 medical centers in 9 of the 10 Canadian provinces. Among these isolates, 20.2% were penicillin nonsusceptible, with 14.6% being penicillin intermediate (MIC, 0.12 to 1 microg/ml) and 5.6% being penicillin resistant (MIC, > or =2 microg/ml). The proportion of high-level penicillin-resistant S. pneumoniae isolates increased from 2.4 to 13.8% over the last 3 years of the study, and the proportion of multidrug-resistant S. pneumoniae isolates increased from 2.7 to 8.8% over the 5-year period. Resistant rates (intermediate and resistant) among non-beta-lactam agents were as follows: macrolides, 9.6 to 9.9%; clindamycin, 3.8%; doxycycline, 5.5%; chloramphenicol, 3.9%; and trimethoprim-sulfamethoxazole, 19.0%. Rates of resistance to non-beta-lactam agents were higher among penicillin-resistant strains than among penicillin-susceptible strains. No resistance to vancomycin or linezolid was observed; however, 0.1% intermediate resistance to quinupristin-dalfopristin was observed. The rate of macrolide resistance (intermediate and resistant) increased from 7.9 to 11.1% over the 5 years. For the fluoroquinolones, the order of activity based on the MICs at which 50% of isolates are inhibited (MIC(50)s) and the MIC(90)s was gemifloxacin > clinafloxacin > trovafloxacin > moxifloxacin > grepafloxacin > gatifloxacin > levofloxacin > ciprofloxacin. The investigational compounds ABT-773 (MIC(90), 0.008 microg/ml), ABT-492 (MIC(90), 0.015 microg/ml), GAR-936 (tigecycline; MIC(90), 0.06 microg/ml), and BMS284756 (garenoxacin; MIC(90), 0.06 micro g/ml) displayed excellent activities. Despite decreases in the rates of antibiotic consumption in Canada over the 5-year period, the rates of both high-level penicillin-resistant and multidrug-resistant S. pneumoniae isolates are increasing in Canada.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760860      PMCID: PMC155828          DOI: 10.1128/AAC.47.6.1867-1874.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae.

Authors:  A Tomasz
Journal:  Am J Med       Date:  1999-07-26       Impact factor: 4.965

Review 2.  Resistance issues and treatment implications: pneumococcus, Staphylococcus aureus, and gram-negative rods.

Authors:  D E Low
Journal:  Infect Dis Clin North Am       Date:  1998-09       Impact factor: 5.982

3.  Increase in pneumococcal bacteraemia in Sweden.

Authors:  J Giesecke; H Fredlund
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

4.  Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides.

Authors:  D J Hoban; A K Wierzbowski; K Nichol; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

5.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.

Authors:  J C Butler; J Hofmann; M S Cetron; J A Elliott; R R Facklam; R F Breiman
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

6.  Genetics of high level penicillin resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  V A Barcus; K Ghanekar; M Yeo; T J Coffey; C G Dowson
Journal:  FEMS Microbiol Lett       Date:  1995-03-01       Impact factor: 2.742

7.  Genetic analysis of clinical isolates of Streptococcus pneumoniae with high-level resistance to expanded-spectrum cephalosporins.

Authors:  T J Coffey; M Daniels; L K McDougal; C G Dowson; F C Tenover; B G Spratt
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

8.  Bacteriology of acute otitis media: a new perspective.

Authors:  M A Del Beccaro; P M Mendelman; A F Inglis; M A Richardson; N O Duncan; C R Clausen; T L Stull
Journal:  J Pediatr       Date:  1992-01       Impact factor: 4.406

9.  Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group.

Authors:  J F Plouffe; R F Breiman; R R Facklam
Journal:  JAMA       Date:  1996-01-17       Impact factor: 56.272

10.  Ribosomal Resistance: Emerging Problems and Potential Solutions.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

View more
  37 in total

1.  Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.

Authors:  H J Smith; A M Noreddin; C G Siemens; K N Schurek; J Greisman; C J Hoban; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  Increasing genetic relatedness of ciprofloxacin-resistant Streptococcus pneumoniae isolated in Canada from 1997 to 2005.

Authors:  Kimberly A Nichol; Heather J Adam; James A Karlowsky; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

3.  Antimicrobial resistance - Judicious use is the key.

Authors:  John M Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-09       Impact factor: 2.471

4.  In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae.

Authors:  George G Zhanel; James A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

Review 5.  Treating acute exacerbations of chronic bronchitis and community-acquired pneumonia: how effective are respiratory fluoroquinolones?

Authors:  M Balter; K Weiss
Journal:  Can Fam Physician       Date:  2006-10       Impact factor: 3.275

Review 6.  Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Authors:  Susan J Keam; Katherine F Croom; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors:  Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Steady-state plasma and intrapulmonary pharmacokinetics and pharmacodynamics of cethromycin.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 10.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.